Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Rotasiil is a live attenuated, pentavalent, human-bovine reassortant rotavirus vaccine developed by the Serum Institute of India (SIIPL). It is designed to provide active immune protection against rotavirus gastroenteritis in infants. The vaccine contains five live attenuated reassortant strains of rotavirus, each combining a human rotavirus surface antigen (serotypes G1, G2, G3, G4, and G9) with a bovine rotavirus (UK strain) backbone. This reassortant approach allows the vaccine to elicit a broad immune response against the most common global rotavirus serotypes. Rotasiil is typically supplied as a lyophilized powder that is reconstituted with a citrate bicarbonate buffer and administered orally as a three-dose series starting at 6 weeks of age. It received approval in India in 2017 and achieved WHO prequalification in 2018, facilitating its use in global immunization programs.
- Brand names
- Rotasiil
- Other names
- live attenuated pentavalent human x bovine reassortant rotavirus vaccinebovine-human rotavirus reassortant pentavalent vaccine
02
Targets
VP7 (Rotavirus A Outer Capsid Glycoprotein VP7 (G9 genotype))VP7 (Rotavirus A outer capsid glycoprotein VP7 (G4 genotype))VP7 (Outer capsid glycoprotein VP7)VP7 (Rotavirus VP7)VP7 (Rotavirus A outer capsid glycoprotein VP7)
Beyond the preview
Go deeper on rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent.